Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type

E. Martignoni, F. Blandini, F. Petraglia, C. Pacchetti, G. Bono, G. Nappi

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Neuropeptide Y, one of the most abundant polypeptides within the nervous system, is co-stored with catecholamines, especially norepinephrine (NE), thus suggesting its possible involvement in pathologies characterized by a noradrenergic impairment. In Parkinson's disease (PD), as well as in multiple system atrophy (MSA), a central noradrenergic deficit has been demonstrated, and in the dementia of Alzheimer type (DAT) an impaired noradrenergic transmission has been postulated. In this study we determined CSF NE and MHPG levels in 29 PD, 15 MSA, 22 DAT patients and in 36 controls, while CSF NPY-immunoreactivity (NPY-ir) levels were measured in 10 PD, 7 MSA, 10 DAT patients and 20 controls. PD, MSA, and DAT patients showed a significant reduction in CSF NPY-ir and NE levels compared with controls, while CSF MHPG levels resulted in a reduction in only the MSA group. Furthermore, an inverse correlation between either NE or MHPG levels and the duration of the orthostatic hypotension was found in MSA patients while for DAT patients the MHPG levels were directly correlated to the severity of cognitive impairment, and inversely to the duration of illness.

Original languageEnglish
Pages (from-to)191-205
Number of pages15
JournalJournal of Neural Transmission - Parkinson's Disease and Dementia Section
Volume4
Issue number3
DOIs
Publication statusPublished - Sep 1992

Fingerprint

Multiple System Atrophy
Neuropeptide Y
Methoxyhydroxyphenylglycol
Parkinson Disease
Cerebrospinal Fluid
Norepinephrine
Alzheimer Disease
Orthostatic Hypotension
Nervous System
Catecholamines
4-hydroxyphenethylene glycol
Pathology
Peptides

Keywords

  • 3-methoxy-4-hydroxyphenylglycol
  • dementia of Alzheimer type
  • multiple system atrophy
  • neuropeptide Y
  • Norepinephrine
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

@article{10fe2c6671524426b13cae8c2ca20eb2,
title = "Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type",
abstract = "Neuropeptide Y, one of the most abundant polypeptides within the nervous system, is co-stored with catecholamines, especially norepinephrine (NE), thus suggesting its possible involvement in pathologies characterized by a noradrenergic impairment. In Parkinson's disease (PD), as well as in multiple system atrophy (MSA), a central noradrenergic deficit has been demonstrated, and in the dementia of Alzheimer type (DAT) an impaired noradrenergic transmission has been postulated. In this study we determined CSF NE and MHPG levels in 29 PD, 15 MSA, 22 DAT patients and in 36 controls, while CSF NPY-immunoreactivity (NPY-ir) levels were measured in 10 PD, 7 MSA, 10 DAT patients and 20 controls. PD, MSA, and DAT patients showed a significant reduction in CSF NPY-ir and NE levels compared with controls, while CSF MHPG levels resulted in a reduction in only the MSA group. Furthermore, an inverse correlation between either NE or MHPG levels and the duration of the orthostatic hypotension was found in MSA patients while for DAT patients the MHPG levels were directly correlated to the severity of cognitive impairment, and inversely to the duration of illness.",
keywords = "3-methoxy-4-hydroxyphenylglycol, dementia of Alzheimer type, multiple system atrophy, neuropeptide Y, Norepinephrine, Parkinson's disease",
author = "E. Martignoni and F. Blandini and F. Petraglia and C. Pacchetti and G. Bono and G. Nappi",
year = "1992",
month = "9",
doi = "10.1007/BF02260903",
language = "English",
volume = "4",
pages = "191--205",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",
number = "3",

}

TY - JOUR

T1 - Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type

AU - Martignoni, E.

AU - Blandini, F.

AU - Petraglia, F.

AU - Pacchetti, C.

AU - Bono, G.

AU - Nappi, G.

PY - 1992/9

Y1 - 1992/9

N2 - Neuropeptide Y, one of the most abundant polypeptides within the nervous system, is co-stored with catecholamines, especially norepinephrine (NE), thus suggesting its possible involvement in pathologies characterized by a noradrenergic impairment. In Parkinson's disease (PD), as well as in multiple system atrophy (MSA), a central noradrenergic deficit has been demonstrated, and in the dementia of Alzheimer type (DAT) an impaired noradrenergic transmission has been postulated. In this study we determined CSF NE and MHPG levels in 29 PD, 15 MSA, 22 DAT patients and in 36 controls, while CSF NPY-immunoreactivity (NPY-ir) levels were measured in 10 PD, 7 MSA, 10 DAT patients and 20 controls. PD, MSA, and DAT patients showed a significant reduction in CSF NPY-ir and NE levels compared with controls, while CSF MHPG levels resulted in a reduction in only the MSA group. Furthermore, an inverse correlation between either NE or MHPG levels and the duration of the orthostatic hypotension was found in MSA patients while for DAT patients the MHPG levels were directly correlated to the severity of cognitive impairment, and inversely to the duration of illness.

AB - Neuropeptide Y, one of the most abundant polypeptides within the nervous system, is co-stored with catecholamines, especially norepinephrine (NE), thus suggesting its possible involvement in pathologies characterized by a noradrenergic impairment. In Parkinson's disease (PD), as well as in multiple system atrophy (MSA), a central noradrenergic deficit has been demonstrated, and in the dementia of Alzheimer type (DAT) an impaired noradrenergic transmission has been postulated. In this study we determined CSF NE and MHPG levels in 29 PD, 15 MSA, 22 DAT patients and in 36 controls, while CSF NPY-immunoreactivity (NPY-ir) levels were measured in 10 PD, 7 MSA, 10 DAT patients and 20 controls. PD, MSA, and DAT patients showed a significant reduction in CSF NPY-ir and NE levels compared with controls, while CSF MHPG levels resulted in a reduction in only the MSA group. Furthermore, an inverse correlation between either NE or MHPG levels and the duration of the orthostatic hypotension was found in MSA patients while for DAT patients the MHPG levels were directly correlated to the severity of cognitive impairment, and inversely to the duration of illness.

KW - 3-methoxy-4-hydroxyphenylglycol

KW - dementia of Alzheimer type

KW - multiple system atrophy

KW - neuropeptide Y

KW - Norepinephrine

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0026553640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026553640&partnerID=8YFLogxK

U2 - 10.1007/BF02260903

DO - 10.1007/BF02260903

M3 - Article

VL - 4

SP - 191

EP - 205

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 3

ER -